Skip to main content

Table 3 Participants’ health status at week 26 (FAS, ANCOVA, LOCF)

From: Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Health status

Placebo (n = 63)

Rasagiline 1 mg (n = 64)

P value

PDQ-39 Dimension

 Summary index

1.97 ± 1.15

0.77 ± 1.12

0.425

Activities of daily living

 Change from baseline

2.49 ± 1.82

1.86 ± 1.79

0.789

Bodily discomfort

   

 Change from baseline

1.28 ± 2.05

2.14 ± 2.01

0.749

Cognition

 Change from baseline

1.60 ± 1.91

−1.97 ± 1.87

0.156

Communication

 Change from baseline

2.10 ± 1.45

1.41 ± 1.42

0.716

Emotional well-being

 Change from baseline

1.43 ± 1.82

−1.62 ± 1.78

0.201

Mobility

 Change from baseline

3.13 ± 1.83

2.60 ± 1.79

0.823

Social support

 Change from baseline

2.91 ± 1.16

2.56 ± 1.14

0.819

Stigma

 Change from baseline

0.59 ± 2.16

−1.32 ± 2.12

0.502

EQ-5D score

EQ-5D Utility index score

 Change from baseline

−0.04 ± 0.02

−0.01 ± 0.02

0.261

EQ-5D VAS score

 Change from baseline

−4.31 ± 1.65

2.49 ± 1.61

0.002

  1. Data are mean ± standard error of the mean. EQ-5D, EuroQol-Five Dimension; PDQ-39, Parkinson’s Disease Questionnaire-39; VAS, visual analog scale
Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us